Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabin-IPV vs Salk-IPV Sequential Schedule in Infants
NCT04051736Phase 4Completed
- Sponsor
- China National Biotec Group
- Start
- Mar 2018
- Primary completion
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sabin strain inactivated poliovirus vaccine in poliomyelitis (2 arms), sponsored by China National Biotec Group. Primary endpoint: Seroconversion rate against type I, Type II and Type III poliomyelitis virus at 4 months. Started Mar 2018; status: completed.
02
Drugs
Sabin strain inactivated poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT04051736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04051736.